Vaxcyte plunges 56% even though its VAX-24 pneumonia vaccine shows positive phase two results in infants. Read more here.

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

Pneumococcal vaccines protect against a type of bacteria, not a virus such as the flu. Many babies or young children now get the recommended pneumococcal vaccine series. It is also recommended for ...

The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

The FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer got a green light for a new version of its market leading Prevnar shot. Merck's Vaxneuvance ...

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

The pivotal Phase III STRIDE-3 trial was one of the key studies, comparing the vaccine against PCV20 in adults who had not ...

The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in ...

Merck’s Capvaxive receives European approval for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults: Rahway, New Jersey Friday, March 28, 2025, 09: ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or ...